



Institut für Pharmazeutische
Wissenschaften

**UNI
GRAZ**

VORTRAGSANKÜNDIGUNG
Im Rahmen des Pharmazeutischen Kolloquiums

(Host: A.J. Kungl)

21. October 2016, 12:15
SR 03.K1, Schubertstraße 1/UG

**Battling Cancer with Bispecific
Antibodies**

Dr. Robert Doornbos
Senior Director Product Development
Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. The company's most advanced development programs use the Biclomics® format. Biclomics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.